Skip Nav Destination
Microbial dysbiosis is associated with aggressive histology and adverse clinical outcome in B-cell non-Hodgkin lymphoma
HLA-haploidentical TCRαβ+/CD19+-depleted stem cell transplantation in children and young adults with Fanconi anemia
A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation
Outcomes and prognostic factors in adolescents and young adults with ALL treated with a modified BFM-90 protocol
Low-dose decitabine for refractory prolonged isolated thrombocytopenia after HCT: a randomized multicenter trial
End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA
Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines
Heterogeneous NLRP3 inflammasome signature in circulating myeloid cells as a biomarker of COVID-19 severity
Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias
Comorbidities and malignancies negatively affect survival in myelodysplastic syndromes: a population-based study
Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis in the rituximab era
Molecular response to imatinib in patients with chronic myeloid leukemia in Tanzania
Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study
Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis
Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML
A neutrophil activation signature predicts critical illness and mortality in COVID-19
Cost-effectiveness of magnetic resonance imaging for diagnosing recurrent ipsilateral deep vein thrombosis
Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome
Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia
First-in-human phase 1 trial of induced regulatory T cells for graft-versus-host disease prophylaxis in HLA-matched siblings
Issue Archive
March 9 2021
In this Issue
Table of Contents
DRUG ADVANCES
EXCEPTIONAL CASE REPORT
STIMULUS REPORTS
Microbial dysbiosis is associated with aggressive histology and adverse clinical outcome in B-cell non-Hodgkin lymphoma
Clinical Trials & Observations
Catherine S. Diefenbach,Brandilyn A. Peters,Huilin Li,Bruce Raphael,Tibor Moskovits,Kenneth Hymes,Jonas Schluter,J. Chen,N. Nora Bennani,Thomas E. Witzig,Jiyoung Ahn
HLA-haploidentical TCRαβ+/CD19+-depleted stem cell transplantation in children and young adults with Fanconi anemia
Clinical Trials & Observations
Luisa Strocchio,Daria Pagliara,Mattia Algeri,Giuseppina Li Pira,Francesca Rossi,Valentina Bertaina,Giovanna Leone,Rita Maria Pinto,Marco Andreani,Emanuele Agolini,Katia Girardi,Stefania Gaspari,Lavinia Grapulin,Francesca del Bufalo,Antonio Novelli,Pietro Merli,Franco Locatelli
REVIEW ARTICLE
CLINICAL TRIALS AND OBSERVATIONS
A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation
Clinical Trials & Observations
Nelli Bejanyan,Joseph A. Pidala,Xuefeng Wang,Ram Thapa,Taiga Nishihori,Hany Elmariah,Aleksandr Lazaryan,Farhad Khimani,Marco L. Davila,Asmita Mishra,Rawan Faramand,Michael D. Jain,Leonel Ochoa,Lia Elena Perez,Hien Liu,Melissa Alsina,Mohamed A. Kharfan-Dabaja,Hugo Fernandez,Michael L. Nieder,Frederick L. Locke,Claudio Anasetti,Ernesto Ayala
Outcomes and prognostic factors in adolescents and young adults with ALL treated with a modified BFM-90 protocol
Clinical Trials & Observations
Akhil Rajendra,Hasmukh Jain,V. N. Avinash Bonda,Lingaraj Nayak,Prashant Tembhare,Dhanlaxmi Shetty,Jayashree Thorat,Hemani Jain,Papagudi Ganesan Subramanian,Nikhil Patkar,Gaurav Chatterjee,Navin Khattry,Anant Gokarn,Sachin Punatar,Smruti Mokal,Bhausaheb Bagal,Manju Sengar
Low-dose decitabine for refractory prolonged isolated thrombocytopenia after HCT: a randomized multicenter trial
Clinical Trials & Observations
Yaqiong Tang,Jia Chen,Qifa Liu,Tiantian Chu,Tingting Pan,Jianying Liang,Xue Feng He,Feng Chen,Ting Yang,Xiao Ma,Xiaojin Wu,Shaoyan Hu,Xingyu Cao,Xiaohui Hu,Jiong Hu,Yuejun Liu,Jiaqian Qi,Yueping Shen,Changgeng Ruan,Yue Han,Depei Wu
End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA
Clinical Trials & Observations
Lale Kostakoglu,Maurizio Martelli,Laurie H. Sehn,David Belada,Angelo-Michele Carella,Neil Chua,Eva Gonzalez-Barca,Xiaonan Hong,Antonio Pinto,Yuankai Shi,Yoichi Tatsumi,Andrea Knapp,Federico Mattiello,Tina Nielsen,Deniz Sahin,Gila Sellam,Mikkel Z. Oestergaard,Umberto Vitolo,Marek Trněný
Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines
Clinical Trials & Observations
Alden A. Moccia,Kimberly Schaff,Ciara Freeman,Paul J. Hoskins,Richard J. Klasa,Kerry J. Savage,Tamara N. Shenkier,Randy D. Gascoyne,Joseph M. Connors,Laurie H. Sehn
Heterogeneous NLRP3 inflammasome signature in circulating myeloid cells as a biomarker of COVID-19 severity
Clinical Trials & Observations
Johan Courjon,Océane Dufies,Alexandre Robert,Laurent Bailly,Cédric Torre,David Chirio,Julie Contenti,Sébastien Vitale,Céline Loubatier,Anne Doye,Christelle Pomares-Estran,Géraldine Gonfrier,Romain Lotte,Patrick Munro,Orane Visvikis,Jean Dellamonica,Valérie Giordanengo,Michel Carles,Laurent Yvan-Charvet,Stoyan Ivanov,Patrick Auberger,Arnaud Jacquel,Laurent Boyer
Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias
Clinical Trials & Observations
Andrew R. Branagan,Eamon Duffy,Geliang Gan,Fangyong Li,Connor Foster,Rakesh Verma,Lin Zhang,Terri L. Parker,Stuart Seropian,Dennis L. Cooper,Debra Brandt,Jeremy Kortmansky,Davit Witt,Thomas M. Ferencz,Kavita M. Dhodapkar,Madhav V. Dhodapkar
GENE THERAPY
Correction of β-thalassemia by CRISPR/Cas9 editing of the α-globin locus in human hematopoietic stem cells
Giulia Pavani,Anna Fabiano,Marine Laurent,Fatima Amor,Erika Cantelli,Anne Chalumeau,Giulia Maule,Alexandra Tachtsidi,Jean-Paul Concordet,Anna Cereseto,Fulvio Mavilio,Giuliana Ferrari,Annarita Miccio,Mario Amendola
HEALTH SERVICES AND OUTCOMES
Comorbidities and malignancies negatively affect survival in myelodysplastic syndromes: a population-based study
Clinical Trials & Observations
Johanne Rozema,on behalf of the HemoBase Population Registry Consortium,Mels Hoogendoorn,on behalf of the HemoBase Population Registry Consortium,Robby Kibbelaar,on behalf of the HemoBase Population Registry Consortium,Eva van den Berg,on behalf of the HemoBase Population Registry Consortium,Nic Veeger,on behalf of the HemoBase Population Registry Consortium,Eric van Roon,on behalf of the HemoBase Population Registry Consortium
HEMATOPOIESIS AND STEM CELLS
IMMUNOBIOLOGY AND IMMUNOTHERAPY
A BCMAxCD3 bispecific T cell–engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells
David J. DiLillo,Kara Olson,Katja Mohrs,Thomas Craig Meagher,Kevin Bray,Olga Sineshchekova,Thomas Startz,Jessica Kuhnert,Marc W. Retter,Stephen Godin,Prachi Sharma,Frank Delfino,John Lin,Eric Smith,Gavin Thurston,Jessica R. Kirshner
LYMPHOID NEOPLASIA
Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis in the rituximab era
Clinical Trials & Observations
Arushi Khurana,Mattia Novo,Grzegorz S. Nowakowski,Kay M. Ristow,Robert J. Spinner,Christopher H. Hunt,Rebecca L. King,Daniel H. Lachance,Thomas M. Habermann,Ivana N. Micallef,Patrick B. Johnston
Impact of event-free survival status after stem cell transplantation on subsequent survival of patients with lymphoma
Ayumi Fujimoto,Tatsuhiko Anzai,Takahiro Fukuda,Naoyuki Uchida,Takanori Ohta,Takehiko Mori,Masashi Sawa,Satoshi Yoshioka,Toshihiro Miyamoto,Hitoji Uchiyama,Yuta Katayama,Ken-ichi Matsuoka,Souichi Shiratori,Hideyuki Nakazawa,Junya Kanda,Tatsuo Ichinohe,Yoshiko Atsuta,Naoto Fujita,Eisei Kondo,Ritsuro Suzuki
MYELOID NEOPLASIA
Molecular response to imatinib in patients with chronic myeloid leukemia in Tanzania
Clinical Trials & Observations
Global Advances
Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study
Clinical Trials & Observations
Damien Luque Paz,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Jérémie Riou,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Emmanuelle Verger,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Bruno Cassinat,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Aurélie Chauveau,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Jean-Christophe Ianotto,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Brigitte Dupriez,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Françoise Boyer,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Maxime Renard,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Olivier Mansier,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Anne Murati,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Jérôme Rey,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Gabriel Etienne,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Véronique Mansat-De Mas,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Suzanne Tavitian,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Olivier Nibourel,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Stéphane Girault,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Yannick Le Bris,on behalf of the French Intergroup of Myeloproliferative Neoplasms,François Girodon,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Dana Ranta,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Jean-Claude Chomel,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Pascale Cony-Makhoul,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Pierre Sujobert,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Margot Robles,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Raouf Ben Abdelali,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Olivier Kosmider,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Laurane Cottin,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Lydia Roy,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Ivan Sloma,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Fabienne Vacheret,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Mathieu Wemeau,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Pascal Mossuz,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Borhane Slama,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Vincent Cussac,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Guillaume Denis,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Anouk Walter-Petrich,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Barbara Burroni,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Nathalie Jézéquel,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Stéphane Giraudier,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Eric Lippert,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Gérard Socié,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Jean-Jacques Kiladjian,on behalf of the French Intergroup of Myeloproliferative Neoplasms,Valérie Ugo,on behalf of the French Intergroup of Myeloproliferative Neoplasms
Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis
Clinical Trials & Observations
Sebastiano Rontauroli,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Sara Castellano,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Paola Guglielmelli,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Roberta Zini,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Elisa Bianchi,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Elena Genovese,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Chiara Carretta,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Sandra Parenti,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Sebastian Fantini,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Selene Mallia,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Lara Tavernari,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Stefano Sartini,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Margherita Mirabile,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Carmela Mannarelli,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Francesca Gesullo,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Annalisa Pacilli,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Daniela Pietra,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Elisa Rumi,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Silvia Salmoiraghi,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Barbara Mora,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Laura Villani,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Andrea Grilli,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Vittorio Rosti,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Giovanni Barosi,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Francesco Passamonti,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Alessandro Rambaldi,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Luca Malcovati,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Mario Cazzola,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Silvio Bicciato,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Enrico Tagliafico,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Alessandro M. Vannucchi,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators,Rossella Manfredini,on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) investigators
Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia
Clinical Trials & Observations
Christopher J. Walker,Krzysztof Mrózek,Hatice Gulcin Ozer,Deedra Nicolet,Jessica Kohlschmidt,Dimitrios Papaioannou,Luke K. Genutis,Marius Bill,Bayard L. Powell,Geoffrey L. Uy,Jonathan E. Kolitz,Andrew J. Carroll,Richard M. Stone,Ramiro Garzon,John C. Byrd,Ann-Kathrin Eisfeld,Albert de la Chapelle,Clara D. Bloomfield
Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis
Florian Renosi,Anne Roggy,Ambre Giguelay,Lou Soret,Pierre-Julien Viailly,Meyling Cheok,Sabeha Biichle,Fanny Angelot-Delettre,Vahid Asnafi,Elizabeth Macintyre,Sandrine Geffroy,Mary Callanan,Tony Petrella,Eric Deconinck,Etienne Daguindau,Véronique Harrivel,Sabrina Bouyer,Véronique Salaun,Pascale Saussoy,Jean Feuillard,Pascal Fuseau,Philippe Saas,Olivier Adotévi,Fabrice Jardin,Christophe Ferrand,Claude Preudhomme,Jacques Colinge,Christophe Roumier,Francine Garnache-Ottou
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML
Clinical Trials & Observations
Maximilian Stahl,Kamal Menghrajani,Andriy Derkach,Alexander Chan,Wenbin Xiao,Jacob Glass,Amber C. King,Anthony F. Daniyan,Christopher Famulare,Bernadette M. Cuello,Troy Z. Horvat,Omar Abdel-Wahab,Ross L. Levine,Aaron D. Viny,Eytan M. Stein,Sheng F. Cai,Mikhail Roshal,Martin S. Tallman,Aaron D. Goldberg
PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS
A neutrophil activation signature predicts critical illness and mortality in COVID-19
Clinical Trials & Observations
Matthew L. Meizlish,Alexander B. Pine,Jason D. Bishai,George Goshua,Emily R. Nadelmann,Michael Simonov,C-Hong Chang,Hanming Zhang,Marcus Shallow,Parveen Bahel,Kent Owusu,Yu Yamamoto,Tanima Arora,Deepak S. Atri,Amisha Patel,Rana Gbyli,Jennifer Kwan,Christine H. Won,Charles Dela Cruz,Christina Price,Jonathan Koff,Brett A. King,Henry M. Rinder,F. Perry Wilson,John Hwa,Stephanie Halene,William Damsky,David van Dijk,Alfred I. Lee,Hyung J. Chun
Proteomic and bioinformatic profiling of neutrophils in CLL reveals functional defects that predispose to bacterial infections
Nirojah Subramaniam,Jenny Bottek,Stephanie Thiebes,Kristina Zec,Matthias Kudla,Camille Soun,Elena de Dios Panal,Julia K. Lill,Aaron Pfennig,Ralf Herrmann,Kirsten Bruderek,Sven Rahmann,Sven Brandau,Patricia Johansson,Hans Christian Reinhardt,Jan Dürig,Martina Seiffert,Thilo Bracht,Barbara Sitek,Daniel Robert Engel
RED CELLS, IRON, AND ERYTHROPOIESIS
MetAP2 inhibition modifies hemoglobin S to delay polymerization and improves blood flow in sickle cell disease
Melanie Demers,Sarah Sturtevant,Kevin R. Guertin,Dipti Gupta,Kunal Desai,Benjamin F. Vieira,Wenjing Li,Alexandra Hicks,Ayman Ismail,Bronner P. Gonçalves,Giuseppe Di Caprio,Ethan Schonbrun,Scott Hansen,Faik N. Musayev,Martin K. Safo,David K. Wood,John M. Higgins,David R. Light
THROMBOSIS AND HEMOSTASIS
Cost-effectiveness of magnetic resonance imaging for diagnosing recurrent ipsilateral deep vein thrombosis
Clinical Trials & Observations
Lisette F. van Dam,Wilbert B. van den Hout,Gargi Gautam,Charlotte E. A. Dronkers,Waleed Ghanima,Jostein Gleditsch,Anders von Heijne,Herman M. A. Hofstee,Marcel M. C. Hovens,Menno V. Huisman,Stan Kolman,Albert T. A. Mairuhu,Mathilde Nijkeuter,Marcel A. van de Ree,Cornelis J. van Rooden,Robin E. Westerbeek,Jan Westerink,Eli Westerlund,Lucia J. M. Kroft,Frederikus A. Klok
Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome
Clinical Trials & Observations
Shruti Chaturvedi,Noor Dhaliwal,Sarah Hussain,Kathryn Dane,Harshvardhan Upreti,Evan M. Braunstein,Xuan Yuan,C. John Sperati,Alison R. Moliterno,Robert A. Brodsky
Population pharmacokinetics of the von Willebrand factor–factor VIII interaction in patients with von Willebrand disease
Laura H. Bukkems,for the OPTI-CLOT Study Group,Jessica M. Heijdra,for the OPTI-CLOT Study Group,Nico C. B. de Jager,for the OPTI-CLOT Study Group,Hendrika C. A. M. Hazendonk,for the OPTI-CLOT Study Group,Karin Fijnvandraat,for the OPTI-CLOT Study Group,Karina Meijer,for the OPTI-CLOT Study Group,Jeroen C. J. Eikenboom,for the OPTI-CLOT Study Group,Britta A. P. Laros-van Gorkom,for the OPTI-CLOT Study Group,Frank W. G. Leebeek,for the OPTI-CLOT Study Group,Marjon H. Cnossen,for the OPTI-CLOT Study Group,Ron A. A. Mathôt,for the OPTI-CLOT Study Group
TRANSPLANTATION
Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia
Clinical Trials & Observations
Antonio Pierini,Loredana Ruggeri,Alessandra Carotti,Franca Falzetti,Simonetta Saldi,Adelmo Terenzi,Claudio Zucchetti,Gianluca Ingrosso,Tiziana Zei,Roberta Iacucci Ostini,Sara Piccinelli,Samanta Bonato,Sara Tricarico,Antonella Mancusi,Sara Ciardelli,Roberto Limongello,Mara Merluzzi,Mauro Di Ianni,Rita Tognellini,Olivia Minelli,Cristina Mecucci,Maria Paola Martelli,Brunangelo Falini,Massimo Fabrizio Martelli,Cynthia Aristei,Andrea Velardi
First-in-human phase 1 trial of induced regulatory T cells for graft-versus-host disease prophylaxis in HLA-matched siblings
Clinical Trials & Observations
Margaret L. MacMillan,Keli L. Hippen,David H. McKenna,Diane Kadidlo,Darin Sumstad,Todd E. DeFor,Claudio G. Brunstein,Shernan G. Holtan,Jeffrey S. Miller,Erica D. Warlick,Daniel J. Weisdorf,John E. Wagner,Bruce R. Blazar
COMMENTARY
-
Cover Image
Cover Image
COVER FIGURE
Ribbon rendering of partial structure of wild-type factor IXa (Protein Data Bank code 1RFN) showing the protease domain in the standard orientation. R338 is highlighted in blue. The amino acids of the catalytic triad (H221, D269, and S365) that form the enzymatic active site are shown in green. See the article by Samelson-Jones et al. - PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Advertisement intended for health care professionals